Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Melanoma 2HIV Infections 2Acquired Immunodeficiency Syndrome 2Skin Neoplasms 1Sarcoma, Kaposi 1Sarcoma 1Neoplasms 1Muscle Neoplasms 1Hepatitis B 1Carcinoma, Hepatocellular 1Adenoviridae Infections 1AIDS-Related Complex 1

Interventions

Ipilimumab 114pembrolizumab 95Nivolumab 91aldesleukin 86Interleukin-2 57Cyclophosphamide 54Dacarbazine 52Vemurafenib 39trametinib 37Temozolomide 37incomplete Freund's adjuvant 35fludarabine phosphate 35sargramostim 32dabrafenib 32fludarabine 26Bevacizumab 26Paclitaxel 22MART-1 Antigen 21Granulocyte-Macrophage Colony-Stimulating Factor 21montanide ISA 51 20Interferon-alpha 20Cisplatin 20Carboplatin 19Sorafenib 18Introns 17Biopsy 17cobimetinib 16Radiosurgery 16atezolizumab 15Radiotherapy 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Melanoma × Tumor Necrosis Factor-alpha × Clear all
NCT00003789 2013-07-16

Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg

National Cancer Institute (NCI)

Phase 3 Completed
216 enrolled
Dermatologic

Melanoma

NCT00001296 2008-03-04

A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma

National Institutes of Health Clinical Center (CC)

Phase 3 Completed
122 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡